 <h1>Bunavail Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>buprenorphine / naloxone</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about buprenorphine / naloxone. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Bunavail.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to buprenorphine / naloxone: film, tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, buprenorphine/naloxone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking buprenorphine / naloxone:</p><p>
<i>More common</i>
</p><ul>
<li>Chills</li>
<li>cough</li>
<li>feeling faint, dizzy, or lightheaded</li>
<li>feeling of warmth or heat</li>
<li>fever</li>
<li>flushing or redness of the skin, especially on the face and neck</li>
<li>headache</li>
<li>hoarseness</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>sweating</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>darkening of the skin</li>
<li>diarrhea</li>
<li>difficulty swallowing</li>
<li>dizziness</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>hives, itching, skin rash</li>
<li>loss of appetite</li>
<li>mental depression</li>
<li>nausea</li>
<li>overactive reflexes</li>
<li>poor coordination</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid weight gain</li>
<li>restlessness shivering talking or acting with excitement you cannot control tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>trembling or shaking twitching</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking buprenorphine / naloxone:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Blurred vision</li>
<li>confusion</li>
<li>difficult or troubled breathing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>drowsiness</li>
<li>irregular, fast, slow, or shallow breathing</li>
<li>pale or blue lips, fingernails, or skin</li>
<li>pinpoint pupils</li>
<li>relaxed and calm feeling</li>
<li>sleepiness</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of buprenorphine / naloxone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty having a bowel movement</li>
<li>lack or loss of strength</li>
<li>stomach pain</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>diarrhea</li>
<li>runny nose</li>
<li>sneezing</li>
<li>stuffy nose</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Burning or sore mouth</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings inside the mouth</li>
<li>decline or loss of libido or sexual desire</li>
<li>irritability</li>
<li>mood swings</li>
<li>poor concentration</li>
<li>redness, swelling, or soreness of the tongue</li>
<li>reduced muscle strength</li>
<li>swelling, inflammation, or redness of the mouth</li>
</ul><p>
<!-- end film, tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to buprenorphine / naloxone: buccal film, sublingual film, sublingual tablet</i></p><h3>General</h3><p>The most commonly observed adverse events included headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain and peripheral edema.  Additionally, oral hypoesthesia was reported with the sublingual film.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pain (22.4%) </p>
<p><b>Common</b> (1% to 10%): Asthenia, chills, pyrexia, malaise, injury, ear pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypothermia, heat stroke</p>
<p><b>Postmarketing reports</b>: Vertigo<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (36.4%) </p>
<p><b>Common</b> (1% to 10%): Migraine, dizziness, hypertonia, paraesthesia, somnolence</p>
<p><b>Uncommon</b> (0.1% to 1%): Amnesia, convulsion, hyperkinesia, speech disorder, tremor</p>
<p> </p>
<p>Buprenorphine:</p>
<p><b>Postmarketing reports</b>: Neonatal withdrawal syndrome including symptoms of hypertonia, neonatal tremor, neonatal agitation, and myoclonus; reports of neonatal convulsions, apnea, respiratory depression, and bradycardia<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Buprenorphine-naloxone:</p>
<p><b>Common</b> (1% to 10%): Pharyngitis, rhinitis, cough, sinusitis, upper respiratory infection, asthma, bronchitis, dyspnea, pneumonia, increased sputum</p>
<p><b>Uncommon</b> (0.1% to 1%): Yawning</p>
<p><b>Frequency not reported</b>: Rhinorrhea</p>
<p></p>
<p>Buprenorphine:</p>
<p><b>Frequency not reported</b>: Significant respiratory depression, coma, death<sup>[Ref]</sup></p><p>There have been postmarketing reports coma and death associated with concomitant use of buprenorphine and benzodiazepines; many of these reports have involved misuse by self-injection.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (12.1%), nausea (15%), abdominal pain (11.2%)</p>
<p><b>Common</b> (1% to 10%): Vomiting, diarrhea, dyspepsia, flatulence, oral hypoesthesia</p>
<p><b>Uncommon</b> (0.1% to 1%): Mouth ulceration, tongue discoloration, tooth abscess, glossodynia, mucosal erythema (oral), toothache</p>
<p><b>Frequency not reported</b>: Stomach discomfort, </p>
<p><b>Postmarketing reports</b>: Stomatitis, glossitis, tongue disorder, pancreatitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Erectile dysfunction, decreased libido</p>
<p><b>Uncommon</b> (0.1% to 1%): Amenorrhea, ejaculation disorder, menorrhagia, metrorrhagia</p>
<p><b>Postmarketing reports</b>: Disorders of pregnancy</p>
<p></p>
<p>Opioids: </p>
<p><b>Postmarketing reports</b>: Adrenal insufficiency, androgen deficiency<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Buprenorphine: </p>
<p><b>Frequency not reported</b>: Hypersensitivity reactions including bronchospasm, angioneurotic edema, and anaphylactic shock; more commonly reported as rash hives, and pruritus</p>
<p></p>
<p>Naloxone: </p>
<p><b>Frequency not reported</b>: Hypersensitivity reactions including bronchospasm, angioneurotic edema, and anaphylactic shock; more commonly reported as rash hives, and pruritus<sup>[Ref]</sup></p><h3>Local</h3><p><b>Postmarketing reports</b>: Glossodynia, oral mucosal erythema, oral hypoesthesia, stomatitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Vasodilation, hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): Angina pectoris, bradycardia, myocardial infarction, palpitations, tachycardia, hypotension, chest pain</p>
<p><b>Postmarketing reports</b>: Peripheral edema, syncope, orthostatic hypotension, heart rate and rhythm disorders<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Amblyopia, lacrimal disorder</p>
<p><b>Uncommon</b> (0.1% to 1%): Conjunctivitis, miosis<sup>[Ref]</sup></p><h3>Hepatic</h3><p>In clinical trials and in postmarketing reports, cases of cytolytic hepatitis and hepatitis with jaundice have been reported in association with buprenorphine use.  The spectrum of abnormalities has ranged from transient asymptomatic elevations of hepatic transaminases to hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy.  The presence of preexisting liver enzyme abnormalities, viral hepatitis, concomitant hepatotoxic drug use, and ongoing IV drug abuse may have played a causative or contributory role.<sup>[Ref]</sup></p><p>Buprenorphine-naloxone: </p>
<p><b>Common</b> (1% to 10%): Abnormal liver function tests</p>
<p></p>
<p>Buprenorphine: </p>
<p><b>Frequency not reported</b>: Cytolytic hepatitis, hepatitis with jaundice, transient asymptomatic elevations of hepatic transaminases, hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, depression, nervousness, abnormal thinking</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal dreams, agitation, apathy, depersonalization, drug dependence, euphoric mood, hostility</p>
<p><b>Frequency not reported</b>: Restlessness, irritability</p>
<p><b>Postmarketing reports</b>: Hallucination, attempted suicide, insomnia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Sweating (14%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, rash, urticaria, ecchymosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Acne, alopecia, dermatitis exfoliative, dry skin, skin mass, herpes simplex, skin nodule</p>
<p><b>Frequency not reported</b>: Piloerection, cold sweat<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urine abnormality</p>
<p><b>Uncommon</b> (0.1% to 1%): Urinary tract infection, vaginal infection, albuminuria, dysuria, hematuria, urinary retention<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Anemia, leucocytosis, leukopenia, lymphadenopathy, thrombocytopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza, infection<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite, hyperglycemia, hyperlipidemia, hypoglycemia, decreased weight<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, muscle spasms, myalgia, rigid neck, leg cramps, joint disorder</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthritis</p>
<p><b>Frequency not reported</b>: Arthralgia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Nephrolithiasis, blood creatinine increased<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Bunavail (buprenorphine-naloxone)." BioDelivery Sciences International, Inc., Raleigh, NC. </p><p id="ref_3">3. "Product Information. Subutex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc, Richmond, VA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. "Product Information. Zubsolv (buprenorphine-naloxone)." Orexo US, Inc, New York City, NY. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How long does Suboxone stay in your system?</li>
<li>How long does Suboxone block opiates?</li>
<li>Does Suboxone show up on a drug test?</li>
<li>Is buprenorphine an opiate / narcotic?</li>
<li>How long does Suboxone withdrawal last?</li>
<li>Does it help with pain?</li>
<li>Can you overdose on Suboxone?</li>
<li>Suboxone vs methadone: What’s the difference?</li>
<li>What are the different types of buprenorphine/naloxone?</li>
<li>How long does Bunavail (buprenorphine/naloxone) block opiates?</li>
<li>Is Suboxone an opiate / narcotic?</li>
<li>Can Bunavail (buprenorphine/naloxone) be cut in half?</li>
<li>Are Bunavail and Suboxone the same thing?</li>
<li>What is the difference between Cassipa and Suboxone sublingual film?</li>
<li>How long does Bunavail (buprenorphine/naloxone) last?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Bunavail (buprenorphine / naloxone)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>61 Reviews</li>
<li>Drug class: narcotic analgesic combinations</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Suboxone, Zubsolv, Cassipa</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Opiate Dependence</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to buprenorphine / naloxone: buccal film, sublingual film, sublingual tablet</i></p><h3>General</h3><p>The most commonly observed adverse events included headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain and peripheral edema.  Additionally, oral hypoesthesia was reported with the sublingual film.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pain (22.4%) </p><p><b>Common</b> (1% to 10%): Asthenia, chills, pyrexia, malaise, injury, ear pain</p><p><b>Uncommon</b> (0.1% to 1%): Hypothermia, heat stroke</p><p><b>Postmarketing reports</b>: Vertigo<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (36.4%) </p><p><b>Common</b> (1% to 10%): Migraine, dizziness, hypertonia, paraesthesia, somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Amnesia, convulsion, hyperkinesia, speech disorder, tremor</p><p> </p><p>Buprenorphine:</p><p><b>Postmarketing reports</b>: Neonatal withdrawal syndrome including symptoms of hypertonia, neonatal tremor, neonatal agitation, and myoclonus; reports of neonatal convulsions, apnea, respiratory depression, and bradycardia<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Buprenorphine-naloxone:</p><p><b>Common</b> (1% to 10%): Pharyngitis, rhinitis, cough, sinusitis, upper respiratory infection, asthma, bronchitis, dyspnea, pneumonia, increased sputum</p><p><b>Uncommon</b> (0.1% to 1%): Yawning</p><p><b>Frequency not reported</b>: Rhinorrhea</p><p></p><p>Buprenorphine:</p><p><b>Frequency not reported</b>: Significant respiratory depression, coma, death<sup>[Ref]</sup></p><p>There have been postmarketing reports coma and death associated with concomitant use of buprenorphine and benzodiazepines; many of these reports have involved misuse by self-injection.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Constipation (12.1%), nausea (15%), abdominal pain (11.2%)</p><p><b>Common</b> (1% to 10%): Vomiting, diarrhea, dyspepsia, flatulence, oral hypoesthesia</p><p><b>Uncommon</b> (0.1% to 1%): Mouth ulceration, tongue discoloration, tooth abscess, glossodynia, mucosal erythema (oral), toothache</p><p><b>Frequency not reported</b>: Stomach discomfort, </p><p><b>Postmarketing reports</b>: Stomatitis, glossitis, tongue disorder, pancreatitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Erectile dysfunction, decreased libido</p><p><b>Uncommon</b> (0.1% to 1%): Amenorrhea, ejaculation disorder, menorrhagia, metrorrhagia</p><p><b>Postmarketing reports</b>: Disorders of pregnancy</p><p></p><p>Opioids: </p><p><b>Postmarketing reports</b>: Adrenal insufficiency, androgen deficiency<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Buprenorphine: </p><p><b>Frequency not reported</b>: Hypersensitivity reactions including bronchospasm, angioneurotic edema, and anaphylactic shock; more commonly reported as rash hives, and pruritus</p><p></p><p>Naloxone: </p><p><b>Frequency not reported</b>: Hypersensitivity reactions including bronchospasm, angioneurotic edema, and anaphylactic shock; more commonly reported as rash hives, and pruritus<sup>[Ref]</sup></p><h3>Local</h3><p><b>Postmarketing reports</b>: Glossodynia, oral mucosal erythema, oral hypoesthesia, stomatitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Vasodilation, hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Angina pectoris, bradycardia, myocardial infarction, palpitations, tachycardia, hypotension, chest pain</p><p><b>Postmarketing reports</b>: Peripheral edema, syncope, orthostatic hypotension, heart rate and rhythm disorders<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Amblyopia, lacrimal disorder</p><p><b>Uncommon</b> (0.1% to 1%): Conjunctivitis, miosis<sup>[Ref]</sup></p><h3>Hepatic</h3><p>In clinical trials and in postmarketing reports, cases of cytolytic hepatitis and hepatitis with jaundice have been reported in association with buprenorphine use.  The spectrum of abnormalities has ranged from transient asymptomatic elevations of hepatic transaminases to hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy.  The presence of preexisting liver enzyme abnormalities, viral hepatitis, concomitant hepatotoxic drug use, and ongoing IV drug abuse may have played a causative or contributory role.<sup>[Ref]</sup></p><p>Buprenorphine-naloxone: </p><p><b>Common</b> (1% to 10%): Abnormal liver function tests</p><p></p><p>Buprenorphine: </p><p><b>Frequency not reported</b>: Cytolytic hepatitis, hepatitis with jaundice, transient asymptomatic elevations of hepatic transaminases, hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, depression, nervousness, abnormal thinking</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal dreams, agitation, apathy, depersonalization, drug dependence, euphoric mood, hostility</p><p><b>Frequency not reported</b>: Restlessness, irritability</p><p><b>Postmarketing reports</b>: Hallucination, attempted suicide, insomnia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Sweating (14%)</p><p><b>Common</b> (1% to 10%): Pruritus, rash, urticaria, ecchymosis</p><p><b>Uncommon</b> (0.1% to 1%): Acne, alopecia, dermatitis exfoliative, dry skin, skin mass, herpes simplex, skin nodule</p><p><b>Frequency not reported</b>: Piloerection, cold sweat<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urine abnormality</p><p><b>Uncommon</b> (0.1% to 1%): Urinary tract infection, vaginal infection, albuminuria, dysuria, hematuria, urinary retention<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Anemia, leucocytosis, leukopenia, lymphadenopathy, thrombocytopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza, infection<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Uncommon</b> (0.1% to 1%): Decreased appetite, hyperglycemia, hyperlipidemia, hypoglycemia, decreased weight<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, muscle spasms, myalgia, rigid neck, leg cramps, joint disorder</p><p><b>Uncommon</b> (0.1% to 1%): Arthritis</p><p><b>Frequency not reported</b>: Arthralgia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Nephrolithiasis, blood creatinine increased<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Bunavail (buprenorphine-naloxone)." BioDelivery Sciences International, Inc., Raleigh, NC. </p><p id="ref_3">3. "Product Information. Subutex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc, Richmond, VA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. "Product Information. Zubsolv (buprenorphine-naloxone)." Orexo US, Inc, New York City, NY. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How long does Suboxone stay in your system?</li>
<li>How long does Suboxone block opiates?</li>
<li>Does Suboxone show up on a drug test?</li>
<li>Is buprenorphine an opiate / narcotic?</li>
<li>How long does Suboxone withdrawal last?</li>
<li>Does it help with pain?</li>
<li>Can you overdose on Suboxone?</li>
<li>Suboxone vs methadone: What’s the difference?</li>
<li>What are the different types of buprenorphine/naloxone?</li>
<li>How long does Bunavail (buprenorphine/naloxone) block opiates?</li>
<li>Is Suboxone an opiate / narcotic?</li>
<li>Can Bunavail (buprenorphine/naloxone) be cut in half?</li>
<li>Are Bunavail and Suboxone the same thing?</li>
<li>What is the difference between Cassipa and Suboxone sublingual film?</li>
<li>How long does Bunavail (buprenorphine/naloxone) last?</li>
</ul><h2>More about Bunavail (buprenorphine / naloxone)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>61 Reviews</li>
<li>Drug class: narcotic analgesic combinations</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Opiate Dependence</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>